Latest On Bristol-Myers Squibb Company PFD CONV 2 (BMYMP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-01-29 04:57 EST | Dividend | A dividend of $0.5 has been announced on Dec 6, 2023. It will be paid Mar 1, 2024 with an ex-dividend date of Jan 29, 2024. | Neutral |  |
| 2023-10-30 05:56 EST | Dividend | A dividend of $0.5 has been announced on Sep 20, 2023. It will be paid Dec 1, 2023 with an ex-dividend date of Oct 30, 2023. | Neutral | |
| 2023-07-31 05:56 EST | Dividend | A dividend of $0.5 has been announced on Jun 14, 2023. It will be paid Sep 1, 2023 with an ex-dividend date of Jul 31, 2023. | Neutral | |
| 2023-05-13 22:34 EST | News | Bristol-Myers Squibb Company (BMY) Presents at Bank of America Securities 2023 Health Care Conference (Transcript) | N/A | |
| 2023-05-01 05:55 EST | Dividend | A dividend of $0.5 has been announced on Mar 3, 2023. It will be paid Jun 1, 2023 with an ex-dividend date of May 1, 2023. | Neutral | |
| 2023-04-27 12:03 EST | News | Bristol-Myers Squibb Company (BMY) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-04-27 12:03 EST | News | Bristol-Myers Squibb Company 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-03-08 02:40 EST | News | Bristol-Myers Squibb Company (BMY) Presents at Cowen 43rd Annual Healthcare Conference (Transcript) | N/A | |
| 2023-02-20 15:29 EST | News | What To Expect From Bristol-Myers Squibb In 2023 | N/A | |
| 2023-02-03 01:25 EST | News | Bristol-Myers Squibb Company (BMY) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-01-30 04:56 EST | Dividend | A dividend of $0.5 has been announced on Dec 8, 2022. It will be paid Mar 1, 2023 with an ex-dividend date of Jan 30, 2023. | Neutral | |
| 2023-01-18 12:57 EST | News | Why Bristol Myers Squibb Is The Better Buy From U.S. Large Cap Pharma | N/A | |
| 2023-01-09 22:13 EST | News | Bristol-Myers Squibb Co. (BMY) J.P. Morgan 41st Annual Healthcare Conference (Transcript) | N/A | |
| 2022-11-16 20:21 EST | News | Bristol-Myers Squibb Company (BMY) Presents at 4th Annual Wolfe Research Healthcare Conference (Transcript) | N/A | |
| 2022-11-07 04:56 EST | Dividend | A dividend of $0.5 has been announced on Sep 14, 2022. It will be paid Dec 1, 2022 with an ex-dividend date of Nov 7, 2022. | Neutral | |
| 2022-10-27 01:04 EST | News | Bristol-Myers Squibb Co (BMY) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-09-13 02:21 EST | News | Bristol-Myers Squibb Co (BMY) Morgan Stanley Global Healthcare Conference Call Transcript | N/A | |
| 2022-09-09 13:28 EST | News | Bristol-Myers Squibb (BMY) Investor Presentations - Slideshow | N/A | |
| 2022-09-08 20:01 EST | News | Bristol-Myers Squibb Company (BMY) Presents at Citi's 17th Annual BioPharma Conference (Transcript) | N/A | |
| 2022-08-08 05:55 EST | Dividend | A dividend of $0.5 has been announced on Jun 15, 2022. It will be paid Sep 1, 2022 with an ex-dividend date of Aug 8, 2022. | Neutral | |
| 2022-07-29 06:25 EST | News | Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-27 11:45 EST | News | Bristol-Myers Squibb Company 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-07-27 11:45 EST | News | Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-06-30 01:59 EST | News | Bristol-Myers Squibb: When Will The Correction End? | N/A | |
| 2022-06-15 17:40 EST | News | Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs 43rd Annual Global Healthcare Conference | N/A | |
| 2022-06-04 10:08 EST | News | Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at Bernstein 38th Annual Strategic Decisions Conference (Transcript) | N/A | |
| 2022-06-02 17:14 EST | News | Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein 38th Annual Strategic Decisions Conference (Transcript) | N/A | |
| 2022-05-09 05:55 EST | Dividend | A dividend of $0.5 has been announced on Mar 1, 2022. It will be paid Jun 1, 2022 with an ex-dividend date of May 9, 2022. | Neutral | |
| 2022-04-29 15:20 EST | News | Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-04-29 15:20 EST | News | Bristol-Myers Squibb Company 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-03-18 03:45 EST | News | Bristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript) | N/A | |
| 2022-02-08 08:36 EST | News | Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-05 05:30 EST | News | Bristol-Myers Squibb Co (BMY) CEO Giovanni Caforio on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-01-31 04:56 EST | Dividend | A dividend of $0.5 has been announced on Dec 13, 2021. It will be paid Mar 1, 2022 with an ex-dividend date of Jan 31, 2022. | Neutral | |
| 2022-01-13 07:00 EST | News | Bristol-Myers Squibb (BMY) Presents At 40th Annual J.P. Morgan Healthcare Conference | N/A | |
| 2022-01-11 20:36 EST | News | Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript) | N/A | |
| 2022-01-11 03:59 EST | News | Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript) | N/A | |
| 2021-11-19 23:02 EST | News | Bristol-Myers Squibb (BMY) Investor Presentation - Slideshow | N/A | |
| 2021-11-08 04:56 EST | Dividend | A dividend of $0.5 has been announced on Sep 9, 2021. It will be paid Dec 1, 2021 with an ex-dividend date of Nov 8, 2021. | Neutral | |
| 2021-10-29 09:01 EST | News | Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-10-28 06:08 EST | News | Bristol Myers Squibb (BMY) CEO Giovanni Caforio on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-10-28 06:07 EST | News | Bristol-Myers Squibb Company 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-09-22 12:02 EST | News | Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at Morgan Stanley 19th Annual Global Healthcare Brokers Conference (Transcript) | N/A | |
| 2021-08-31 18:01 EST | News | Bristol Myers Squibb: Why Wall Street Is Wrong About The Stock | N/A | |
| 2021-08-09 05:57 EST | Dividend | A dividend of $0.5 has been announced on Jun 17, 2021. It will be paid Sep 1, 2021 with an ex-dividend date of Aug 9, 2021. | Neutral | |
| 2021-07-30 04:41 EST | News | Bristol-Myers Squibb Company 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-07-29 07:48 EST | News | Bristol Myers Squibb (BMY) CEO Giovanni Caforio on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-22 10:33 EST | News | Bristol-Myers Squibb Company (BMY) Management Presents at UBS Global Healthcare 2021 Virtual Conference (Transcript) | N/A | |
| 2021-07-22 10:30 EST | News | Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein's 37th Annual Strategic Decisions Conference (Transcript) | N/A | |
| 2021-07-22 10:28 EST | News | Bristol-Myers Squibb Company's (BMY) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript) | N/A | |
About Bristol-Myers Squibb Company PFD CONV 2 (BMYMP):
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
General
- Name Bristol-Myers Squibb Company PFD CONV 2
- Symbol BMYMP
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorOther
- IndustryOther
- Full Time Employees 23,700
- Fiscal Year EndDecember
Valuation
- Trailing PE 4755.56
Financials
- Most Recent Quarter 2020-12-31
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 1.75 trillion
- PE Ratio 12.36
Share Statistics
- % Held by Insiders <1%
Technicals
- 52 Week High $1497.19
- 52 Week Low $779.44
- 50 Day Moving Average 1116.25
- 200 Day Moving Average 1115.1
Dividends
- Forward Annual Dividend Yield 0.12%
- Dividend Date 2021-06-01
- ExDividend Date N/A
- Dividend Per Share $1.59
- Dividend Yield 0%
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Dividend Calendar:
BMYMP's last dividend payment was made to shareholders on June 1, 2021.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $10.54 billion | -$4.45 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $10.13 billion | $0.82 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $10.78 billion | -$0.04 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $7.95 billion | -$0.34 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $6.01 billion | -$0.55 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $6.27 billion | $0.83 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $5.92 billion | $0.87 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $1.04 | $0.00 | ||
| 2018-09-30 | 2018-12-31 | $0.71 | $0.00 | ||
| 2018-06-30 | 2018-09-30 | $1.16 | $0.00 | ||
| 2018-03-31 | 2018-06-30 | $5.19 billion | $0.23 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $5.45 billion | $0.91 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $5.25 billion | -$1.43 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $5.14 billion | $0.51 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $4.93 billion | $0.56 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $0.94 | $0.00 | ||
| 2016-09-30 | 2016-12-31 | $0.53 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | $0.72 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.69 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.71 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.12 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.42 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.08 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.71 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.01 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.43 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.20 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.56 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.43 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.42 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.32 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.37 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.56 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.43 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.38 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.64 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.50 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.56 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.52 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.57 | $0.00 |
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Chart:
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) News:
Below you will find a list of latest news for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|